Close Menu

NEW YORK – The China National Medical Products Administration (NMPA) has approved Agilent Technologies' PD-L1 IHC 22C3 pharmaDx assay for marketing in that country, the company said today.

Santa Clara, California-based Agilent said that the assay is now approved as a companion diagnostic to identify patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with tumors that express PD-L1 for first-line treatment with Merck's anti-PD-L1 immunotherapy pembrolizumab (Keytruda).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.